A novel alpha‐amylase inhibitor‐based spirooxindole‐pyrrolidine ‐clubbed thiochromene‐pyrzaole pharmacophores: Unveiling the [3+2] cycloaddition reaction by molecular electron density theory
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Mohammad Shahidul Islam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Pyrrolidines, alpha-Amylases, Enzyme Inhibitors, Benzopyrans. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Ministry of Science and Innovation (MICINN) of the Spanish Government, King Saud University.
Abstract (Originalsprache)
A novel spirooxindole‐pyrrolidine clubbed thiochromene and pyrazole motifs were synthesized by [3+2] cycloaddition (32CA) reactions in one step process starting from the ethylene‐based thiochromene and pyrazole scaffolds with the secondary amino‐acids and substituted isatins in high yield. The 32CA reaction of AY 10 with ethylene derivative 6 has also been studied with Molecular Electron Density Theory. The high nucleophilic character of AY 10, N = 4.39 eV, allows explaining that the most favorable TS‐on is 13.9 kcal mol −1 below the separated reagent. This 32CA, which takes place through a non‐concerted one‐step mechanism, presents a total ortho regio‐ and endo stereoselectivity, which is controlled by the formation of two intramolecular H … O hydrogen bonds. The design of spirooxindole‐pyrrolidines engrafted thiochromene and pyrazole was tested for alpha‐amylase inhibition and show a high efficacy in nanoscale range of reactivity. The key interaction between the most active hybrids and the receptor was studied by molecular docking. The physiochemical properties of the designed spirooxindole‐pyrrolidines were carried out by in silico ADMET prediction. The newly synthesized most potent hybrid could be considered as a lead compound for drug discovery development for type 2 diabetes mellitus (T2DM).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
- Department of Chemistry, University of Jyväskylä, Jyväskylä, Finland.
- Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan, Pakistan.
- Department of Molecular Biology and Biochemistry, University of California, Irvine, California, USA.
- Department of Organic Chemistry, University of Valencia, Valencia, Spain.
ORCID-Profile: Zahida Parveen, Assem Barakat
Förderung
- Ministry of Science and Innovation (MICINN) of the Spanish Government
- King Saud University
Zitieren
APA
Islam, M. S., Al-Majid, A. M., Haukka, M., Parveen, Z., Ravaiz, N., Wadood, A., Rehman, A. U., Ríos-Gutiérrez, M., Domingo, L. R., & Barakat, A. (2023). A novel alpha‐amylase inhibitor‐based spirooxindole‐pyrrolidine ‐clubbed thiochromene‐pyrzaole pharmacophores: Unveiling the [3+2] cycloaddition reaction by molecular electron density theory. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14299
Vancouver
Islam MS, Al-Majid AM, Haukka M, Parveen Z, Ravaiz N, Wadood A, et al. A novel alpha‐amylase inhibitor‐based spirooxindole‐pyrrolidine ‐clubbed thiochromene‐pyrzaole pharmacophores: Unveiling the [3+2] cycloaddition reaction by molecular electron density theory. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14299
BibTeX
@article{Islam2023,
author = {Islam, Mohammad Shahidul and Al-Majid, Abdullah Mohammed and Haukka, Matti and Parveen, Zahida and Ravaiz, Nabeela and Wadood, Abdul and Rehman, Ashfaq Ur and Ríos-Gutiérrez, Mar and Domingo, Luis R and Barakat, Assem},
title = {A novel alpha‐amylase inhibitor‐based spirooxindole‐pyrrolidine ‐clubbed thiochromene‐pyrzaole pharmacophores: Unveiling the [3+2] cycloaddition reaction by molecular electron density theory},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14299}
}
EUVIMED